Gilead Sciences Announces Third Quarter 2015 Dividend

Gilead Sciences' (GILD) Price Target Bumped to $135 at Deutsche Bank

Deutsche Bank maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) and raised its price target to $135.00 (from $125.00). Analyst Robyn Karnauskas characterized Q2 results as "solid" and said HCV discounts don't look bad.

"We are lowering our US HCV revenues while increasing OUS numbers & model WW revs at $18.5B vs.... More

Gilead Sciences (GILD) PT Lifted to $135 at Baird on Strong Earnings Beat

Baird analyst Brian Skorney lifted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $135.00 (from $126.00) following earnings beat.

Skorney commented, "Gilead handily beat expectations, across the board, and raised revenue guidance yet again. Interestingly, nothing in Hep C declined... More

Gilead Sciences (GILD) PT Raised to $120 at Oppenheimer on Solid Q2 Beat

Oppenheimer analyst Wendy Lam reiterated an Outperform rating and boosted her price target on Gilead Sciences (NASDAQ: GILD) to $120.00 (from $86.00) following solid the Q2 beat.

Lam commented, "GILD reported a healthy 2Q15 EPS and product revenues beat ($3.15/$8.13B vs. $2.71/$7.60B consensus) underpinned by... More

Gilead Sciences (GILD) Declares $0.43 Quarterly Dividend; 1.5% Yield

Gilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.43 per share, or $1.72 annualized.

The dividend will be payable on September 29, 2015, to stockholders of record on September 16, 2015, with an ex-dividend date of September 14, 2015.

The annual yield on the dividend is 1.5... More

Gilead Sciences (GILD) Tops Q2 EPS by 44c

Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $3.15, $0.44 better than the analyst estimate of $2.71. Revenue for the quarter came in at $8.24 billion versus the consensus estimate of $7.61 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.